The purpose of this study is to evaluate the effectiveness and security of lobaplatin combined with docetaxel in treatment of the sensitive recurrent ovarian cancer.

Inclusion Criteria:

1. age between 18 and 70 years old
2. singed the information consent form
3. Expected survival time >3 months
4. Recurrence for at least 6 months after receiving initial platinum-based chemotherapy and without cytoreductive surgery indications.

Exclusion Criteria:

1. Recurrence within 6 months after receiving initial platinum-based chemotherapy
2. without radiographic evidence for tumor recurrence
3. receiving other chemotherapy, hormone therapy, immunotherapy, or radiation therapy

residents of a certain town